Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranolazine for Maintenance of Sinus Rhythm in AFib
NCT01534962Phase 2Completed
- Sponsor
- Menarini Group
- Start
- Jan 2012
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of ranolazine in Atrial fibrillation (AFib) (4 arms), sponsored by Menarini Group. Primary endpoint: Time From Randomization to First Documented AF Recurrence at 16 weeks. Started Jan 2012; status: completed.
02
Drugs
ranolazine
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT01534962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01534962.